Azetukalner

9 trials 6 recruiting NNeurology/Psychiatry

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

6 Recruiting

2 Completed trials

1 Sponsors

18 Countries

Phase III

Phase II

Phase III: 8 Phase II: 1

Oversight events:

2 serious breaches across 2 trials

View oversight register →

Indications tested

Generalised tonic-clonic seizure 1

Sponsors using this IMP

Xenon Pharmaceuticals Inc. 9

All trials

9 total

An Open-label Study of Azetukalner in Bipolar I or II Depression Pending

2025-522872-10-00 Phase III 4 countries Xenon Pharmaceuticals Inc.
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE… Recruiting

2025-522775-29-00 Phase III 4 countries Xenon Pharmaceuticals Inc.
An Open-label Study of Azetukalner in Major Depressive Disorder Recruiting

2025-523618-10-00 Phase III 6 countries Xenon Pharmaceuticals Inc.
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting

2025-523202-32-00 Phase III 7 countries Xenon Pharmaceuticals Inc.
A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting

2022-502286-16-00 Phase III 12 countries Xenon Pharmaceuticals Inc.
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Phase III 16 countries Xenon Pharmaceuticals Inc.
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting

2022-502281-25-00 Phase III 14 countries Xenon Pharmaceuticals Inc.
A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilep… Ended

2023-508681-15-00 Phase II 3 countries Xenon Pharmaceuticals Inc.
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Phase III 9 countries Xenon Pharmaceuticals Inc.

Showing 1–9 of 9 trials

← All drugs A–Z